Oncology Drugs - Benelux

Benelux

The projected revenue in the Oncology Drugs market in Benelux is estimated to reach US$2.28bn in 2024.
It is expected to experience an annual growth rate (CAGR 2024-2028) of 13.62%, leading to a market volume of US$3.80bn by 2028.
In comparison to other countries, United States is anticipated to generate the highest revenue, amounting to US$114,600.00m in 2024.
The Benelux region is witnessing a surge in the development and adoption of innovative oncology drugs, positioning it as a leading hub for cancer research and treatment in Europe.

Key regions: Germany, India, United Kingdom, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Oncology Drugs market in Benelux has been experiencing steady growth in recent years, driven by several key factors.

Customer preferences: Patients in Benelux are increasingly seeking personalized treatment options for their cancer, leading to a rise in demand for targeted therapies. Additionally, there is a growing awareness of the benefits of early cancer detection, leading to an increase in demand for screening and diagnostic tools.

Trends in the market: One major trend in the Oncology Drugs market in Benelux is the increasing use of immunotherapy, which harnesses the body's own immune system to fight cancer. This approach has shown promising results in treating certain types of cancer and is expected to continue to gain traction in the region. Another trend is the growing importance of biosimilars, which are lower-cost versions of biologic drugs. As patents for many biologics expire, biosimilars are expected to become increasingly prevalent in the market.

Local special circumstances: Benelux countries have a strong tradition of universal healthcare coverage, which means that the cost of cancer treatment is largely covered by the government. This has helped to ensure that patients have access to the latest treatments, regardless of their ability to pay. However, this also means that healthcare budgets are under pressure, leading to a focus on cost containment measures.

Underlying macroeconomic factors: The overall economic growth in Benelux has been steady, which has supported the growth of the Oncology Drugs market. However, there are concerns about the impact of Brexit on the region, particularly in terms of trade and investment. Additionally, the aging population in Benelux is expected to increase the incidence of cancer in the coming years, which will further drive demand for Oncology Drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.